LifeSci Capital Reiterates Buy Rating on Veradermics, Inc.
LifeSci Capital maintains a buy rating on Veradermics, setting a $135 price target.
Key Points
- LifeSci Capital reiterated its buy rating on Veradermics, Inc. (NYSE:MANE) with a price target of $135 on June 16, 2026.
- Veradermics shares traded at $96.27, with a market cap of about $3.8 billion and a 52-week high of $117.71.
- Investment firms like Ameriprise Financial and Jennison Associates have significant stakes in Veradermics.
LifeSci Capital has reiterated its buy rating on Veradermics, Incorporated (NYSE:MANE) with a price target of $135. This reaffirmation by analyst Rami Katkhuda was announced on June 16, 2026. Veradermics shares are currently trading at $96.27.
Other Institutional Activity in Veradermics
Several investment firms have shown interest in Veradermics. Ameriprise Financial Inc has established a position with 514,035 shares valued at approximately $32.5 million. Jennison Associates LLC holds 141,781 shares worth about $8.95 million. Emerald Advisers, LLC has 132,536 shares valued at around $8.37 million, while Emerald Mutual Fund Advisers Trust owns 109,283 shares worth approximately $6.9 million. Seven Grand Managers, LLC and Bamco Inc /NY/ also hold significant stakes.
Veradermics Stock Snapshot
Shares of Veradermics, Inc. (NYSE:MANE) are trading at $96.27. The company has a market capitalization of approximately $3.8 billion. Its stock has traded between a 52-week low of $32.00 and a high of $117.71. Veradermics has a forward P/E ratio that is not meaningful as the company is not currently profitable. The company's 50-day moving average is $92.38, while the 200-day moving average is $73.62. It boasts a robust current ratio of 59.12 and a quick ratio of 58.44, indicating strong liquidity.
Analysts Set New Price Targets
On June 16, 2026, LifeSci Capital reiterated its buy rating on Veradermics, setting a price target of $135. Earlier, Needham initiated coverage with a buy rating and a $136 target on June 2, 2026. Citigroup maintained its buy rating with a $135 target on May 18, 2026. The consensus among analysts is a strong buy, with an average price target of $132.25 based on four analyst opinions.
About Veradermics, Inc.
Veradermics, Incorporated is a biopharmaceutical company based in New Haven, Connecticut. Founded in 2019, it focuses on developing innovative treatments for dermatologic and aesthetic conditions. The company is working on therapies for pattern hair loss, alopecia areata, and other skin conditions. Its product portfolio includes VDPHL01 for hair loss and VDMN for common warts. Dr. Reid Waldman M.D. serves as the CEO.
Bottom Line
LifeSci Capital's reiterated buy rating and $135 price target highlight confidence in Veradermics' potential. Investors track such ratings for insights into a company's growth prospects. However, it's important to remember that analyst ratings are based on current data and projections, which can change over time.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.